The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity

Nature

Volumn 483, Issue 7391, 2012, Pages 603-607

  Barretina, Jordi ^a,b,c   Caponigro, Giordano ^c   Stransky, Nicolas ^a   Venkatesan, Kavitha ^c   Margolin, Adam A ^a,g   Kim, Sungjoon ^d   Wilson, Christopher J ^c   Lehár, Joseph ^c   Kryukov, Gregory V ^a   Sonkin, Dmitriy ^c   Reddy, Anupama ^c   Liu, Manway ^c   Murray, Lauren ^a   Berger, Michael F ^a,h   Monahan, John E ^c   Morais, Paula ^a   Meltzer, Jodi ^c   Korejwa, Adam ^a   Jané Valbuena, Judit ^a,b   Mapa, Felipa A ^c   Thibault, Joseph ^d   Bric Furlong, Eva ^c   Raman, Pichai ^c   Shipway, Aaron ^d   Engels, Ingo H ^d   Cheng, Jill ^c   Yu, Guoying K ^c   Yu, Jianjun ^c   Aspesi, Peter ^c   De Silva, Melanie ^c   Jagtap, Kalpana ^c   Jones, Michael D ^c   Wang, Li ^c   Hatton, Charles ^b   Palescandolo, Emanuele ^b   Gupta, Supriya ^a   Mahan, Scott ^a   Sougnez, Carrie ^a   Onofrio, Robert C ^a   Liefeld, Ted ^a   MacConaill, Laura ^b   Winckler, Wendy ^a   Reich, Michael ^a   Li, Nanxin ^d   Mesirov, Jill P ^a   Gabriel, Stacey B ^a   Getz, Gad ^a   Ardlie, Kristin ^a   Chan, Vivien ^c   Myer, Vic E ^c   Weber, Barbara L ^c   Porter, Jeff ^c   Warmuth, Markus ^c   Finan, Peter ^c   Harris, Jennifer L ^d   Meyerson, Matthew ^a,b   Golub, Todd R ^a,b,e,f   Morrissey, Michael P ^c   Sellers, William R ^c   Schlegel, Robert ^c   Garraway, Levi A ^a,b   more..

^a BROAD INSTITUTE OF MIT AND HARVARD   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

^c NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH   (United States)

^d Genomics Institute   (United States)

^e DANA FARBER CANCER INSTITUTE   (United States)

^f HOWARD HUGHES MEDICAL INSTITUTE   (United States)

^g SAGE BIONETWORKS   (United States)

^h MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2 (2 AMINO 3 METHOXYPHENYL)CHROMONE; ANTINEOPLASTIC AGENT; B RAF KINASE; CHIR 265; DNA TOPOISOMERASE INHIBITOR; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ERLOTINIB; K RAS PROTEIN; LAPATINIB; MITOGEN ACTIVATED PROTEIN KINASE KINASE INHIBITOR; N (2,3 DIHYDROXYPROPOXY) 3,4 DIFLUORO 2 (2 FLUORO 4 IODOANILINO)BENZAMIDE; PANOBINOSTAT; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PLX 4720; ROMIDEPSIN; SHORT HAIRPIN RNA; SOMATOMEDIN C RECEPTOR; SOMATOMEDIN C RECEPTOR INHIBITOR; TOPOTECAN; UNCLASSIFIED DRUG; VORINOSTAT;

CANCER; CELL ORGANELLE; CHROMOSOME; DRUG; GENE EXPRESSION; GENOME; INHIBITOR; TUMOR;

ACUTE LYMPHOBLASTIC LEUKEMIA; ARTICLE; BREAST CANCER; CANCER CELL; COLORECTAL CANCER; COPY NUMBER VARIATION; DRUG EFFICACY; DRUG RESPONSE; EWING SARCOMA; GENE EXPRESSION; GLIOMA; HUMAN; HUMAN CELL; IN VITRO STUDY; KIDNEY CANCER; LIVER CANCER; LUNG CANCER; MELANOMA; NEUROBLASTOMA; OVARY CANCER; PRIORITY JOURNAL; SINGLE NUCLEOTIDE POLYMORPHISM;

EID: 84859169877     PISSN: 00280836     EISSN: 14764687     Source Type: Journal    
DOI: 10.1038/nature11003     Document Type: Article

References (27)

1. Caponigro, G. & Sellers, W. R. Advances in the preclinical testing of cancer therapeutic hypotheses. Nature Rev. Drug Discov. 10, 179-187 (2011).
2. MacConaill, L. E. & Garraway, L. A. Clinical implications of the cancer genome. J. Clin. Oncol. 28, 5219-5228 (2010).
3. Lin, W. M. et al. Modeling genomic diversity and tumor dependency in malignant melanoma. Cancer Res. 68, 664-673 (2008).
4. Neve, R. M. et al. A collection of breast cancer cell lines for the study of functionally distinct cancer subtypes. Cancer Cell 10, 515-527 (2006).
5. Sos, M. L. et al. Predicting drug susceptibility of non-small cell lung cancers based on genetic lesions. J. Clin. Invest. 119, 1727-1740 (2009).
6. Dry, J. R. et al. Transcriptional pathway signatures predict MEK addiction and response to selumetinib (AZD6244). Cancer Res. 70, 2264-2273 (2010).
7. Garraway, L. A. et al. Integrative genomic analyses identifyMITF as a lineage survival oncogene amplified in malignant melanoma. Nature 436, 117-122 (2005).
8. Greshock, J. et al. Molecular target class is predictive of in vitro response profile. Cancer Res. 70, 3677-3686 (2010).
9. McDermott, U. et al. Identification of genotype-correlated sensitivity to selective kinase inhibitors by using high-throughput tumor cell line profiling. Proc. Natl Acad. Sci. USA 104, 19936-19941 (2007).
10. Solit, D. B. et al. BRAF mutation predicts sensitivity to MEK inhibition. Nature 439, 358-362 (2006).
11. Staunton, J. E. et al. Chemosensitivity prediction by transcriptional profiling. Proc. Natl Acad. Sci. USA 98, 10787-10792 (2001).
12. Weinstein, J. N. et al. An information-intensive approach to the molecular pharmacology of cancer. Science 275, 343-349 (1997).
13. Thomas, R. K. et al. High-throughput oncogene mutation profiling in human cancer. Nature Genet. 39, 347-351 (2007).
14. Beroukhim, R. et al. The landscape of somatic copy-number alteration across human cancers. Nature 463, 899-905 (2010).
15. Ross, D. T. et al. Systematic variation in gene expression patterns in human cancer cell lines. Nature Genet. 24, 227-235 (2000).
16. Zou, H. & Hastie, T. Regularization and variable selection via the elastic net. J. R. Stat. Soc. B 67, 301-320 (2005).
17. Konecny, G. E. et al. Activity of the dual kinase inhibitor lapatinib (GW572016) against HER-2-overexpressing and trastuzumab-treated breast cancer cells. Cancer Res. 66, 1630-1639 (2006).
18. Tsai, J. et al. Discovery of a selective inhibitor of oncogenic B-Raf kinase with potent antimelanoma activity. Proc. Natl Acad. Sci. USA 105, 3041-3046 (2008).
19. Zou, H. Y. et al. An orally available small-molecule inhibitor of c-Met, PF-2341066, exhibits cytoreductive antitumor efficacy through antiproliferative and antiangiogenic mechanisms. Cancer Res. 67, 4408-4417 (2007).
20. Mü ller C. R. et al. Potential for treatment of liposarcomas with the MDM2 antagonist Nutlin-3A. Int. J. Cancer 121 199-205 (2007).
21. Nishio, M. et al. Serum heparan sulfate concentration is correlated with the failure of epidermal growth factor receptor tyrosine kinase inhibitor treatment in patients with lung adenocarcinoma. J. Thorac. Oncol. 6, 1889-1894 (2011).
22. Guo,W. et al. Formation of 17-allylamino-demethoxygeldanamycin (17-AAG) hydroquinonebyNAD(P)H:quinoneoxidoreductase1:roleof17-AAGhydroquinone in heat shock protein 90 inhibition. Cancer Res. 65, 10006-10015 (2005).
23. Kelland, L. R., Sharp, S. Y., Rogers, P. M., Myers, T. G.&Workman, P. DT-Diaphorase expression and tumor cell sensitivity to 17-allylamino, 17-demethoxygeldanamycin, an inhibitor of heat shock protein 90. J. Natl Cancer Inst. 91, 1940-1949 (1999).
24. Moreau,P. et al.PhaseI studyof theanti insulin-likegrowthfactor1receptor (IGF-1R) monoclonalantibody,AVE1642,assingleagentandincombinationwithbortezomib in patientswith relapsedmultiplemyeloma. Leukemia 25, 872-874 (2011).
25. Reiners, J. J. Jr, Lee, J. Y., Clift, R. E., Dudley, D. T. & Myrand, S. P. PD98059 is an equipotent antagonist of the aryl hydrocarbon receptor and inhibitor of mitogenactivated protein kinase kinase. Mol. Pharmacol. 53, 438-445 (1998).
26. Wagner, L. M. et al. Temozolomide and intravenous irinotecan for treatment of advanced Ewing sarcoma. Pediatr. Blood Cancer 48, 132-139 (2007).
27. Garnett, M. J. et al. Systematic identification of genomicmarkers of drug sensitivity in cancer cells. Nature http://dx.doi.org/10.1038/nature11005 (this issue).